Skip to content

Bone Marrow-Derived Stem Cells: A Mixed Blessing in the Multifaceted World of Diabetic Complications

Research output: Contribution to journalArticle

Original languageEnglish
Article number43
Number of pages12
JournalCurrent diabetes reports
Issue number5
Early online date30 Mar 2016
DateAccepted/In press - 1 Feb 2016
DateE-pub ahead of print - 30 Mar 2016
DatePublished (current) - 1 May 2016


Diabetes is one of the main economic burdens in health care, which threatens to worsen dramatically if prevalence forecasts are correct. What makes diabetes harmful is the multi-organ distribution of its microvascular and macrovascular complications. Regenerative medicine with cellular therapy could be the dam against life-threatening or life-altering complications. Bone marrow-derived stem cells are putative candidates to achieve this goal. Unfortunately, the bone marrow itself is affected by diabetes, as it can develop a microangiopathy and neuropathy similar to other body tissues. Neuropathy leads to impaired stem cell mobilization from marrow, the so-called mobilopathy. Here, we review the role of bone marrow-derived stem cells in diabetes: how they are affected by compromised bone marrow integrity, how they contribute to other diabetic complications, and how they can be used as a treatment for these. Eventually, we suggest new tactics to optimize stem cell therapy.

    Research areas

  • Bone marrow, Cell regenerative therapy, Diabetes, Diabetic complications, Microangiopathy, Stem cells

Download statistics

No data available



  • art%3A10.1007%2Fs11892-016-0730-x

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Current Medicine Group at 10.1007/s11892-016-0730-x. Please refer to any applicable terms of use of the publisher.

    Final published version, 466 KB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups